Peter A van Dam
Overview
Explore the profile of Peter A van Dam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
959
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Debie Y, Garcia-Fogeda I, Willem L, Roelant E, Verbruggen L, Vanhoutte G, et al.
Sci Rep
. 2025 Mar;
15(1):7858.
PMID: 40050359
The level of protection against SARS-CoV-2 breakthrough infections conferred by the presence of anti-S1 SARS-CoV-2 antibodies (IgGs) in cancer patients is still understudied. This work examines the existence of an...
2.
Oner G, Praet M, Stoop H, Devi G, Canturk N, Altintas S, et al.
Breast Cancer (Dove Med Press)
. 2025 Feb;
17:211-224.
PMID: 40008212
Background: Tumor-associated macrophages (TAMs) constitute an important part of the tumor microenvironment of breast cancer (BC), and they play an essential role in modulating tumor growth and invasion. However, the...
3.
Berneman Z, De Laere M, Germonpre P, Huizing M, Willemen Y, Lion E, et al.
J Hematol Oncol
. 2025 Jan;
18(1):9.
PMID: 39849594
Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment options for patients with malignancies. We evaluated the feasibility, safety, immunogenicity, and clinical activity of adjuvant...
4.
De Jaeghere E, Tuyaerts S, Van Nufel A, Belmans A, Bogaerts K, Baiden-Amissah R, et al.
Cancer Immunol Immunother
. 2024 Dec;
74(1):32.
PMID: 39738642
No abstract available.
5.
De Jaeghere E, Hamerlinck H, Tuyaerts S, Lippens L, Van Nuffel A, Baiden-Amissah R, et al.
Gynecol Oncol
. 2024 Nov;
191():275-286.
PMID: 39515198
Background: The phase II PRIMMO trial investigated a pembrolizumab-based regimen in patients with recurrent and/or metastatic cervical (CC) or endometrial (EC) carcinoma who had at least one prior line of...
6.
Debie Y, Palte Z, Salman H, Verbruggen L, Vanhoutte G, Chhajlani S, et al.
Qual Life Res
. 2024 Jul;
33(10):2845-2853.
PMID: 38961007
Introduction: Long COVID is defined as the continuation of symptoms, unexplainable by alternative diagnosis, longer than four weeks after SARS-CoV-2 infection. These symptoms might hinder daily activities and overall well-being,...
7.
Aronson S, Lopez-Yurda M, Koole S, Schagen van Leeuwen J, Schreuder H, Hermans R, et al.
Lancet Oncol
. 2023 Sep;
24(10):1109-1118.
PMID: 37708912
Background: The OVHIPEC-1 trial previously showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in improved progression-free and overall survival compared with cytoreductive surgery alone...
8.
Oner G, Broeckx G, Van Berckelaer C, Zwaenepoel K, Altintas S, Canturk Z, et al.
Cancer Med
. 2023 Aug;
12(17):17901-17913.
PMID: 37553911
Background: Oestrogen receptor positive (ER+)/HER-2 negative breast cancer (BC) is considered to be an immunologically cold tumour compared to triple negative breast cancer. Therefore, the tumour microenvironment (TME) of ER+/HER-2...
9.
Debie Y, van Dam P, Goossens M, Peeters M, Vandamme T
Eur J Cancer
. 2022 Dec;
179:121-123.
PMID: 36521333
No abstract available.
10.
Debie Y, Van Audenaerde J, Vandamme T, Croes L, Teuwen L, Verbruggen L, et al.
Clin Cancer Res
. 2022 Nov;
29(3):635-646.
PMID: 36341493
Purpose: Patients with cancer display reduced humoral responses after double-dose COVID-19 vaccination, whereas their cellular response is more comparable with that in healthy individuals. Recent studies demonstrated that a third...